|
End-of-day quote
Bratislava S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 17.20 EUR | +1.18% |
|
+1.18% | +72.00% |
| 04-28 | Biotika a.s. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 25-09-25 | Biotika a.s. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 12.04M 13.97M 11.29M 10.3M 19.41M 1.34B 19.47M 134M 52.26M 674M 52.46M 51.32M 2.24B | P/E 2024 |
-4.39x | P/E 2025 | -5.89x |
|---|---|---|---|---|---|
| Enterprise Value | 8.33M 9.66M 7.81M 7.13M 13.42M 923M 13.47M 92.61M 36.13M 466M 36.28M 35.49M 1.55B | EV / Sales 2024 |
0.55x | EV / Sales 2025 | 0.18x |
| Free-Float |
42.84% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.18% | ||
| 1 week | +1.18% | ||
| Current month | -14.00% | ||
| 1 month | -15.69% | ||
| 3 months | +62.26% | ||
| 6 months | +81.05% | ||
| Current year | +72.00% |
| 1 week | 17.2 |  | 17.2 |
| 1 month | 17 | | 17.2 |
| Current year | 9 | | 23 |
| 1 year | 7 | | 23 |
| 3 years | 7 | | 25 |
| 5 years | 7 | | 42 |
| 10 years | 7 | | 50.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marek Tarda
CEO | Chief Executive Officer | - | - |
P. Zila
CTO | Chief Tech/Sci/R&D Officer | - | - |
Milan Zemko
CIO | Chief Investment Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Dasa Bokorova
CHM | Chairman | - | - |
Filip Novak
BRD | Director/Board Member | - | - |
Anna Valachova
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.18% | +1.18% | +115.00% | -21.82% | 14.03M | |
| +0.35% | +0.84% | +19.98% | +73.55% | 48.07B | |
| -0.08% | -3.41% | +55.31% | +125.50% | 40.17B | |
| +0.15% | +7.52% | +20.56% | +89.26% | 12.42B | |
| +0.25% | -1.01% | -9.89% | +17.70% | 12.01B | |
| +0.19% | +0.19% | +30.98% | +150.00% | 9.38B | |
| +0.07% | +0.30% | +27.45% | +46.12% | 7.78B | |
| +0.04% | -0.99% | +52.61% | -10.90% | 7.24B | |
| +2.24% | +7.81% | +28.93% | +240.12% | 7.27B | |
| -0.53% | -6.81% | -35.67% | +17.62% | 5.33B | |
| Average | +0.39% | -0.25% | +30.53% | +72.71% | 14.97B | |
| Weighted average by Cap. | +0.23% | +0.24% | +28.23% | +89.68% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 17.24M 20.01M 16.16M 14.76M 27.8M 1.91B 27.88M 192M 74.82M 965M 75.11M 73.48M 3.2B | 18.15M 21.07M 17.02M 15.54M 29.27M 2.01B 29.36M 202M 78.79M 1.02B 79.1M 77.37M 3.37B |
| Net income | -2.39M -2.77M -2.24M -2.05M -3.85M -265M -3.87M -26.59M -10.37M -134M -10.41M -10.19M -444M | -1.19M -1.38M -1.11M -1.02M -1.92M -132M -1.92M -13.23M -5.16M -66.57M -5.18M -5.07M -221M |
| Net Debt | -1.07M -1.24M -999K -912K -1.72M -118M -1.72M -11.85M -4.62M -59.63M -4.64M -4.54M -198M | -3.71M -4.31M -3.48M -3.18M -5.99M -412M -6.01M -41.32M -16.12M -208M -16.18M -15.83M -690M |
Employees
165
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- 1BSL01AE Stock
Select your edition
All financial news and data tailored to specific country editions
